Symbols / ALLR Stock $1.49 +0.00% Allarity Therapeutics, Inc.

Healthcare • Biotechnology • United States • NCM
ALLR (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Thomas H. Jensen
Exch · Country NCM · United States
Market Cap 23.04M
Enterprise Value 7.99M
Income -11.23M
Sales 320.00K
FCF (ttm) -10.21M
Book/sh 0.52
Cash/sh 0.93
Employees 7
Insider 10d —
IPO Dec 21, 2021
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E 0.11
Forward P/E -1.54
PEG —
P/S 71.99
P/B 2.89
P/C —
EV/EBITDA -0.63
EV/Sales 24.95
Quick Ratio 1.86
Current Ratio 2.13
Debt/Eq 14.24
LT Debt/Eq —
EPS (ttm) -0.70
EPS next Y -0.97
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-15
Earnings (prior) 2026-05-15
ROA -38.52%
ROE -103.80%
ROIC —
Gross Margin 100.00%
Oper. Margin -9.12%
Profit Margin 0.00%
Shs Outstand 15.46M
Shs Float 15.74M
Insider Own 4.85%
Instit Own 6.15%
Short Float 1.78%
Short Ratio 2.16
Short Interest 274.06K
52W High 2.35
vs 52W High -36.60%
52W Low 0.77
vs 52W Low 93.76%
Beta 0.38
Impl. Vol. —
Rel Volume 0.77
Avg Volume 175.01K
Volume 135.48K
Target (mean) $9.75
Tgt Median $9.75
Tgt Low $9.75
Tgt High $9.75
# Analysts 1
Recom None
Prev Close $1.49
Price $1.49
Change 0.00%
About

Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing anti-cancer therapeutics for patients with unmet medical needs in Denmark and the United States. The company develops drugs for the personalized treatment of cancer using drug-specific companion diagnostics generated by its proprietary drug response predictor (DRP) technology. Its lead drug candidate is stenoparib, a dual inhibitor of poly-ADP-ribose polymerase (PARP1/2), which is in a Phase 2 clinical trial for patients with advanced and recurrent ovarian cancer. It is also developing stenoparib with temozolomide, a PARP and WNT inhibitor in combination with a DNA-alkylating chemotherapy agent, which is in a Phase 2 clinical trial for patients with relapsed small cell lung cancer; and stenoparib-DRP, a companion diagnostic product used to select patients for stenoparib treatment. Allarity Therapeutics, Inc. is headquartered in Tarpon Springs, Florida.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$9.75
Mean price target
2. Current target
$1.49
Latest analyst target
3. DCF / Fair value
$-11.89
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.49
Low
$9.75
High
$9.75
Mean
$9.75

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-10 main Ascendiant Capital Buy → Buy $10
2025-12-09 main Ascendiant Capital Buy → Buy $10
2025-07-28 init Ascendiant Capital — → Buy $9
News
RSS: Latest ALLR news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-01-28 MCLAUGHLIN GERALD W Director — 45,000 $0.00 $0
2026-01-28 JENSEN THOMAS Chief Executive Officer — 200,000 $0.00 $0
2026-01-28 GRAFF JEREMY R. President — 133,333 $0.00 $0
2026-01-28 ERVIN JEFFREY S. Chief Financial Officer — 150,000 $0.00 $0
2026-01-07 GRAFF JEREMY R. President — 133,333 $0.00 $0
2025-09-30 GRAFF JEREMY R. President — 39,494 — —
2025-01-22 JENSEN THOMAS Chief Executive Officer — 396,734 $0.00 $0
2025-01-22 GRAFF JEREMY R. Officer — 144,441 $0.00 $0
2025-01-22 EPSHINSKY ALEXANDER Chief Financial Officer — 29,496 $0.00 $0
2024-09-30 GRAFF JEREMY R. President — 118,483 $2.11 $249,999
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.32
0.00
0.00
0.00
Operating Revenue
0.32
0.00
0.00
0.00
Operating Expense
12.93
-26.30%
17.54
+2.39%
17.13
+1.40%
16.89
Research And Development
6.60
+8.28%
6.10
-14.18%
7.10
+2.50%
6.93
Selling General And Administration
6.32
-44.73%
11.44
+14.12%
10.03
+0.64%
9.96
General And Administrative Expense
6.32
-44.73%
11.44
+14.12%
10.03
+0.64%
9.96
Other Gand A
6.32
-44.73%
11.44
+14.12%
10.03
+0.64%
9.96
Total Expenses
12.93
-26.30%
17.54
+2.39%
17.13
+1.40%
16.89
Operating Income
-12.61
+28.13%
-17.54
-2.39%
-17.13
-1.40%
-16.89
Total Operating Income As Reported
-12.61
+53.73%
-27.24
-59.03%
-17.13
+50.30%
-34.46
EBITDA
-11.05
+54.42%
-24.23
-114.78%
-11.28
+34.77%
-17.30
Normalized EBITDA
-11.80
+30.55%
-17.00
+3.77%
-17.66
-5.11%
-16.80
Reconciled Depreciation
-0.01
-244.44%
0.01
-75.68%
0.04
-38.33%
0.06
EBIT
-11.05
+54.44%
-24.24
-114.16%
-11.32
+34.78%
-17.36
Total Unusual Items
0.76
+110.47%
-7.24
-213.48%
6.38
+1391.09%
-0.49
Total Unusual Items Excluding Goodwill
0.76
+110.47%
-7.24
-213.48%
6.38
+1391.09%
-0.49
Special Income Charges
0.00
+100.00%
-9.70
0.00
+100.00%
-16.59
Other Special Charges
—
—
—
0.80
Impairment Of Capital Assets
0.00
-100.00%
9.70
0.00
-100.00%
17.57
Net Income
-11.23
+54.19%
-24.52
-105.99%
-11.90
+25.89%
-16.06
Pretax Income
-11.23
+54.89%
-24.90
-110.66%
-11.82
+32.77%
-17.58
Net Non Operating Interest Income Expense
0.62
+613.33%
-0.12
+74.79%
-0.48
-146.63%
-0.19
Interest Expense Non Operating
0.18
-71.67%
0.65
+31.12%
0.50
+123.32%
0.22
Net Interest Income
0.62
+613.33%
-0.12
+74.79%
-0.48
-146.63%
-0.19
Interest Expense
0.18
-71.67%
0.65
+31.12%
0.50
+123.32%
0.22
Interest Income Non Operating
0.80
+50.28%
0.53
+2322.73%
0.02
-26.67%
0.03
Interest Income
0.80
+50.28%
0.53
+2322.73%
0.02
-26.67%
0.03
Other Income Expense
0.76
+110.47%
-7.24
-225.07%
5.79
+1271.46%
-0.49
Other Non Operating Income Expenses
—
—
-0.59
—
Gain On Sale Of Security
0.76
-69.25%
2.46
-61.35%
6.38
-60.38%
16.10
Tax Provision
0.00
+100.00%
-0.38
-559.04%
0.08
+105.46%
-1.52
Tax Rate For Calcs
0.00
-100.00%
0.00
-92.71%
0.00
+142.71%
0.00
Tax Effect Of Unusual Items
0.00
+100.00%
-0.11
-108.27%
1.34
+3233.59%
-0.04
Net Income Including Noncontrolling Interests
-11.23
+54.19%
-24.52
-105.99%
-11.90
+25.89%
-16.06
Net Income From Continuing Operation Net Minority Interest
-11.23
+54.19%
-24.52
-105.99%
-11.90
+25.89%
-16.06
Net Income From Continuing And Discontinued Operation
-11.23
+54.19%
-24.52
-105.99%
-11.90
+25.89%
-16.06
Net Income Continuous Operations
-11.23
+54.19%
-24.52
-105.99%
-11.90
+25.89%
-16.06
Minority Interests
—
—
—
—
Normalized Income
-11.99
+31.05%
-17.39
-2.65%
-16.94
-8.54%
-15.61
Net Income Common Stockholders
-11.23
+55.35%
-25.15
-23.21%
-20.42
+3.02%
-21.05
Diluted EPS
—
-15.65
+99.74%
-6,031.31
+81.03%
-31,799.09
Basic EPS
—
-15.65
+99.74%
-6,031.31
+81.03%
-31,799.09
Basic Average Shares
—
1.61
+47373.83%
0.00
+411.33%
0.00
Diluted Average Shares
—
1.61
+47373.83%
0.00
+411.33%
0.00
Diluted NI Availto Com Stockholders
-11.23
+55.35%
-25.15
-23.21%
-20.42
+3.02%
-21.05
Gain On Sale Of PPE
—
—
0.00
-100.00%
1.78
Preferred Stock Dividends
—
0.64
-92.50%
8.52
+70.54%
4.99
Total Other Finance Cost
—
—
—
—
Line Item Trend 2025-12-31 2023-12-31
Total Assets
18.26
+53.92%
11.86
Current Assets
17.93
+809.59%
1.97
Cash Cash Equivalents And Short Term Investments
14.69
+8747.59%
0.17
Cash And Cash Equivalents
14.69
+8747.59%
0.17
Cash Financial
14.69
+8747.59%
0.17
Other Short Term Investments
—
—
Receivables
0.90
-5.39%
0.95
Accounts Receivable
0.00
0.00
Taxes Receivable
0.90
-5.39%
0.95
Prepaid Assets
2.35
+173.11%
0.86
Current Deferred Assets
—
0.00
Total Non Current Assets
0.33
-96.66%
9.89
Net PPE
0.33
+1550.00%
0.02
Gross PPE
0.33
+1550.00%
0.02
Accumulated Depreciation
—
—
Other Properties
0.33
+1550.00%
0.02
Goodwill And Other Intangible Assets
—
9.87
Other Intangible Assets
—
9.87
Investments And Advances
—
—
Total Liabilities Net Minority Interest
8.43
-42.31%
14.61
Current Liabilities
8.43
-40.50%
14.17
Payables And Accrued Expenses
7.03
-28.15%
9.78
Payables
4.36
-48.52%
8.47
Accounts Payable
4.28
-49.12%
8.42
Current Accrued Expenses
2.67
+103.74%
1.31
Total Tax Payable
0.08
+37.29%
0.06
Income Tax Payable
0.08
+37.29%
0.06
Current Debt And Capital Lease Obligation
1.40
+7.69%
1.30
Current Debt
1.40
+7.69%
1.30
Other Current Borrowings
1.40
+7.69%
1.30
Current Capital Lease Obligation
—
0.00
Other Current Liabilities
—
3.08
Total Non Current Liabilities Net Minority Interest
0.00
-100.00%
0.45
Long Term Debt And Capital Lease Obligation
—
—
Long Term Debt
—
—
Long Term Capital Lease Obligation
—
—
Non Current Deferred Liabilities
—
0.45
Non Current Deferred Taxes Liabilities
—
0.45
Preferred Securities Outside Stock Equity
—
0.00
Stockholders Equity
9.83
+457.25%
-2.75
Common Stock Equity
9.83
+318.74%
-4.49
Capital Stock
0.00
-99.83%
1.74
Common Stock
0.00
0.00
Preferred Stock
—
1.74
Share Issued
19.03
+193872.27%
0.01
Ordinary Shares Number
16.08
+163807.65%
0.01
Treasury Shares Number
2.95
0.00
Additional Paid In Capital
144.23
+59.60%
90.37
Retained Earnings
-130.20
-37.85%
-94.45
Gains Losses Not Affecting Retained Earnings
-1.02
-148.42%
-0.41
Treasury Stock
3.19
—
Other Equity Adjustments
-1.02
-148.42%
-0.41
Total Equity Gross Minority Interest
9.83
+457.25%
-2.75
Total Capitalization
9.83
+457.25%
-2.75
Working Capital
9.50
+177.88%
-12.20
Invested Capital
11.23
+451.64%
-3.19
Total Debt
1.40
+7.69%
1.30
Net Debt
—
1.13
Capital Lease Obligations
—
0.00
Net Tangible Assets
9.83
+177.86%
-12.62
Tangible Book Value
9.83
+168.42%
-14.36
Available For Sale Securities
—
—
Current Notes Payable
—
0.00
Derivative Product Liabilities
—
—
Interest Payable
0.46
+356.44%
0.10
Investmentin Financial Assets
—
—
Line Of Credit
—
—
Preferred Stock Equity
—
1.74
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-14.82
+14.59%
-17.35
-36.15%
-12.74
+24.21%
-16.82
Cash Flow From Continuing Operating Activities
-14.82
+14.59%
-17.35
-36.15%
-12.74
+24.21%
-16.82
Net Income From Continuing Operations
-11.23
+54.19%
-24.52
-105.99%
-11.90
+25.89%
-16.06
Depreciation Amortization Depletion
-0.01
-244.44%
0.01
-75.68%
0.04
-38.33%
0.06
Depreciation And Amortization
-0.01
-244.44%
0.01
-75.68%
0.04
-38.33%
0.06
Other Non Cash Items
0.39
-31.98%
0.57
-64.04%
1.57
+1040.58%
0.14
Stock Based Compensation
0.48
+578.87%
0.07
+200.00%
-0.07
-104.05%
1.75
Asset Impairment Charge
0.00
-100.00%
9.70
0.00
-100.00%
17.57
Deferred Tax
0.00
+100.00%
-0.45
-559.79%
0.10
+106.02%
-1.61
Deferred Income Tax
0.00
+100.00%
-0.45
-559.79%
0.10
+106.02%
-1.61
Operating Gains Losses
1.24
+144.13%
-2.80
+51.95%
-5.83
+68.20%
-18.34
Gain Loss On Investment Securities
-0.00
+99.96%
-2.68
+52.65%
-5.65
+66.76%
-17.01
Net Foreign Currency Exchange Gain Loss
1.24
+1082.54%
-0.13
+29.61%
-0.18
-139.78%
0.45
Gain Loss On Sale Of PPE
—
—
0.00
+100.00%
-1.78
Change In Working Capital
-5.68
-9115.87%
0.06
-98.12%
3.35
+1121.95%
-0.33
Change In Receivables
-0.10
-313.33%
0.04
+273.08%
-0.03
0.00
Changes In Account Receivables
—
—
—
—
Change In Prepaid Assets
-1.60
-685.04%
0.27
+244.21%
-0.19
+69.26%
-0.62
Change In Payables And Accrued Expense
-3.83
-587.79%
-0.56
-125.02%
2.23
+51.84%
1.47
Change In Accrued Expense
-2.70
-176.33%
3.54
+8123.26%
0.04
+100.91%
-4.72
Change In Payable
-1.13
+72.34%
-4.09
-287.49%
2.18
-64.72%
6.19
Change In Account Payable
-1.14
+72.27%
-4.11
-289.75%
2.17
-65.12%
6.21
Change In Other Working Capital
—
0.21
—
—
Change In Other Current Assets
-0.15
-259.57%
0.09
-93.04%
1.35
+225.35%
-1.08
Change In Other Current Liabilities
—
0.00
+100.00%
-0.01
+91.92%
-0.10
Investing Cash Flow
-0.01
+97.32%
-0.30
0.00
-100.00%
0.79
Cash Flow From Continuing Investing Activities
-0.01
+97.32%
-0.30
0.00
-100.00%
0.79
Net PPE Purchase And Sale
-0.01
+97.32%
-0.30
0.00
+100.00%
-0.02
Purchase Of PPE
-0.01
+97.32%
-0.30
0.00
+100.00%
-0.02
Capital Expenditure
-0.01
+97.32%
-0.30
—
-0.02
Net Intangibles Purchase And Sale
—
—
0.00
-100.00%
0.81
Financing Cash Flow
10.65
-71.06%
36.79
+234.62%
10.99
+938.67%
-1.31
Cash Flow From Continuing Financing Activities
10.65
-71.06%
36.79
+234.62%
10.99
+938.67%
-1.31
Net Issuance Payments Of Debt
0.00
0.00
+100.00%
-2.65
-364.90%
1.00
Issuance Of Debt
0.00
-100.00%
1.34
+27.62%
1.05
+5.00%
1.00
Repayment Of Debt
0.00
+100.00%
-1.34
+63.77%
-3.70
0.00
Long Term Debt Issuance
0.00
-100.00%
1.34
+27.62%
1.05
+5.00%
1.00
Long Term Debt Payments
0.00
+100.00%
-1.34
+63.77%
-3.70
0.00
Net Long Term Debt Issuance
0.00
0.00
+100.00%
-2.65
-364.90%
1.00
Net Short Term Debt Issuance
—
—
—
0.00
Net Common Stock Issuance
10.65
-71.49%
37.35
+121.09%
16.89
0.00
Common Stock Payments
-3.19
0.00
—
—
Repurchase Of Capital Stock
-3.19
+8.86%
-3.50
+47.40%
-6.65
-340.37%
-1.51
Proceeds From Stock Option Exercised
—
0.00
-100.00%
2.24
0.00
Net Other Financing Charges
—
—
—
-0.80
Changes In Cash
-4.18
-121.83%
19.14
+1193.83%
-1.75
+89.91%
-17.34
Effect Of Exchange Rate Changes
-0.67
-396.44%
0.23
+299.12%
-0.11
+40.21%
-0.19
Beginning Cash Position
19.53
+11666.87%
0.17
-91.82%
2.03
-89.62%
19.55
End Cash Position
14.69
-24.81%
19.53
+11666.87%
0.17
-91.82%
2.03
Free Cash Flow
-14.83
+15.99%
-17.65
-38.49%
-12.74
+24.29%
-16.84
Interest Paid Supplemental Data
—
—
0.03
-60.00%
0.09
Income Tax Paid Supplemental Data
—
—
0.01
-50.00%
0.01
Change In Income Tax Payable
0.01
-53.33%
0.01
-16.67%
0.02
+194.74%
-0.02
Change In Tax Payable
0.01
-53.33%
0.01
-16.67%
0.02
+194.74%
-0.02
Common Stock Issuance
13.84
-62.95%
37.35
+121.09%
16.89
0.00
Issuance Of Capital Stock
13.84
-65.66%
40.29
+123.16%
18.05
0.00
Net Preferred Stock Issuance
0.00
+100.00%
-0.56
+89.77%
-5.49
-263.60%
-1.51
Preferred Stock Issuance
0.00
-100.00%
2.94
+153.28%
1.16
0.00
Preferred Stock Payments
0.00
+100.00%
-3.50
+47.40%
-6.65
-340.37%
-1.51
Sale Of Intangibles
—
—
0.00
-100.00%
0.81
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category